Life Sciences

Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.



Sign up for a 7-day FREE trial today!



Latest News in Life Sciences

  • August 25, 2026

    Albertsons Witness Says Co.'s Opioid Policies Beat Standards

    Albertsons' pharmacy policies for reviewing potentially suspicious opioid prescriptions "met or exceeded" the standard of care, an expert witness for the company testified Tuesday, on the 26th day of a bench trial in Washington's case accusing the pharmacy chain of fueling the state's opioid epidemic.

  • August 25, 2026

    Ex-Taro Exec Slips Some Generics Price-Fixing Claims

    A Connecticut federal judge gave a former Taro Pharmaceuticals USA Inc. marketing executive a partial victory in generic drug price-fixing litigation, tossing several claims by state attorneys general but allowing others to proceed after finding that a jury could conclude he joined certain conspiracies.

  • August 25, 2026

    Health Exec Says CFO, Atty Knew Wage Claim Was Wrong

    A former corporate officer has sued his ex-colleague and the colleague's attorney in Connecticut state court, alleging they named him as a personal defendant in a federal wage lawsuit without any factual basis and with the intent to pressure his company into settling claims it disputed.

  • August 25, 2026

    AIDS Org 'Had Its Chance' To Sue Express Scripts, Judge Says

    Express Scripts convinced a Missouri federal judge Tuesday to dismiss an AIDS Healthcare Foundation antitrust suit the judge said was precluded by a rejected earlier case in the same district raising the "same facts and circumstances" accusing the pharmacy benefit manager of imposing lower reimbursement rates on specialty pharmacies.

  • August 25, 2026

    Marijuana Rescheduling Critics Assail Government's Standard

    An attorney with the U.S. Drug Enforcement Administration told an administrative law judge that opponents to cannabis rescheduling could not use agency hearings to challenge federal health regulators' adoption of a new standard for assessing marijuana's medical use.

See more Life Sciences news

Life Sciences

Areas of Coverage

  • AGENCIES
  • U.S. Consumer Product Safety Commission
  • U.S. Food and Drug Administration
  • U.S. Patent and Trademark Office
  • U.S. International Trade Commission
  • POLICY & REGULATION
  • Affordable Care Act
  • Federal Food, Drug, and Cosmetic Act
  • Antitrust and consumer protection controls
  • Drug and medical device lobbying
  • State and international life sciences legislation and regulation
  • ENFORCEMENT
  • Drug and medical device recalls
  • Drug safety actions
  • Pay-for-delay investigations
  • Merger reviews
  • LITIGATION
  • Patent disputes, including
  • Abbreviated New Drug Application litigation
  • Section 301 cases
  • Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
  • Consumer litigation and class actions
  • Fraud and compliance suits
  • Antitrust disputes
  • Labor and employment suits
  • Shareholder and corporate governance disputes
  • Bankruptcy proceedings
  • TRANSACTIONS
  • Mergers, acquisitions, and joint ventures
  • Share buybacks and stock splits
  • Private equity deals
  • Patent-licensing agreements
  • PROFILES
  • Personnel moves
  • Profiles of life sciences practice groups

Readership

  • Life sciences lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the drug, biotechnology, and medical device industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals